Russian courts have sharpened Article 54.1 scrutiny across pharmaceuticals in 2026. Here is what in-house counsel needs to know and do now. Make an enquiry.
Following a sustained period of Federal Tax Service enforcement activity across the pharmaceuticals sector, Russian courts have entered 2026 with a markedly more demanding standard for what constitutes a legitimate business arrangement under the unjustified tax benefit doctrine codified in Article 54.1 of the Russian Tax Code. Foreign companies operating Russian pharmaceutical subsidiaries, joint ventures, or distribution structures should treat the developments described in this update as directly relevant to the risk profile of their existing arrangements – not merely as background reading.
Before the current enforcement cycle, pharmaceutical companies could generally satisfy Article 54.1 scrutiny by demonstrating that a transaction had a genuine commercial purpose and that the counterparty had formally performed its contractual obligations. Courts broadly accepted documentary evidence – contracts, invoices, delivery records – as sufficient to rebut FTS assertions of unjustified tax benefit, provided the company could show that goods or services had in fact changed hands.
The approach that has emerged in recent court practice, and that the Federal Tax Service has now systematically applied to pharmaceutical sector audits, is materially more stringent. Courts have increasingly moved beyond formal compliance with the documentary standard and now examine whether the counterparty possessed – at the time of the transaction – the actual economic capacity to perform: qualified personnel, operating infrastructure, proprietary or licensed know-how, and demonstrable industry-specific resources. For pharmaceutical companies, this means that intermediary structures used for distribution, logistics co-ordination, or regulatory affairs support face particular scrutiny, because these functions require sector-specific competencies that a shell or thinly staffed entity cannot credibly demonstrate.
A second shift concerns the treatment of intra-group arrangements. Russian courts have been more willing to look through the legal form of transactions between related parties – particularly where pricing, margin allocation, or the allocation of intangible-related income does not reflect what the FTS considers consistent with the substance of the parties' contributions. In the pharmaceuticals context, this has affected arrangements involving the use of trademarks, know-how licences, and centralised marketing or pharmacovigilance services routed through group companies. The absence of contemporaneous economic analysis explaining the pricing of such services has, in a number of recent matters, weighed decisively against the taxpayer.
The Foreign Tax Service has identified the pharmaceutical sector as a priority area for Article 54.1 scrutiny. Several structural features of pharmaceutical distribution and manufacturing in Russia make the sector particularly exposed.
Foreign subsidiaries and wholly owned manufacturing entities. Foreign-owned Russian manufacturing or packaging entities that rely on intra-group supply of active pharmaceutical ingredients, proprietary formulations, or manufacturing know-how are subject to dual exposure: the pricing of those inputs may be challenged under transfer-pricing rules, while the underlying arrangements may simultaneously be assessed under Article 54.1 if the court finds that the economic substance of the relationship differs from its legal form. In-house counsel at multinational pharmaceutical companies should note that the FTS has been applying both instruments in parallel, rather than treating them as alternative characterisation tools.
Distributors and logistics intermediaries. Multi-tier distribution structures – common in Russian pharmaceutical markets, where a foreign principal supplies through a Russian importer and one or more sub-distributors – are directly in scope of the current enforcement approach. Where the intermediate entities in the chain lack the personnel, storage capacity, or cold-chain infrastructure to have genuinely performed their contractual role, courts have upheld FTS disallowance of deductible costs and input VAT credits throughout the chain. The risk is not confined to the entity immediately in front of the auditor: courts have, in some instances, examined the entire supply chain when assessing whether the primary taxpayer acted in bad faith.
Research and regulatory-affairs service recipients. Russian entities that contract with foreign group companies for regulatory support, clinical trial co-ordination, or pharmacovigilance services have also been subject to challenge, on the basis that the foreign entity lacked verifiable substance in Russia at the point of performance. The practical difficulty is that legitimate cross-border service arrangements of this kind are structurally difficult to distinguish – from a court's perspective – from arrangements designed primarily to shift income offshore. Companies that have not constructed a contemporaneous record of actual service delivery, with evidence of the specific outputs received and the personnel involved, are in a weaker position.
EAEU market participants. Given Russia's role as the dominant regulatory authority within the Eurasian Economic Union pharmaceutical framework, companies that operate across EAEU markets through Russian legal entities face the additional complexity that their Russian subsidiary's commercial rationale may be scrutinised in the context of group-wide EAEU market strategy. Pricing and margin allocation decisions made at the group level for EAEU market reasons may not be readily explicable within the narrower Article 54.1 documentary framework that Russian courts apply.
For in-house counsel managing a Russian pharmaceutical subsidiary, the regulatory timeline and the FTS's stated sectoral priorities leave limited margin for delay in reviewing existing arrangements against the standards now being applied in court.
If your Russian subsidiary or distribution structure operates in the pharmaceutical sector and has not been reviewed against the current Article 54.1 standard, make an enquiry: info@vetrovpartners.com |
The practical response to the current enforcement environment is not primarily a question of tax planning – it is a question of documentation and structure maintenance. The following steps reflect what the firm has advised clients operating in analogous positions.
First, review the substance profile of every Russian entity in your pharmaceutical supply or service chain. This means assessing whether each entity has, and can demonstrate having had, the personnel, premises, and sector-specific capacity required to perform the functions attributed to it. Where gaps exist, they should be documented and addressed before an audit commences, not after.
Second, reconstruct or compile contemporaneous records for intra-group service arrangements. Courts have placed significant weight on the quality and contemporaneity of internal documentation – meeting minutes, delivery reports, personnel records, email chains confirming specific deliverables. After-the-fact reconstruction is legally available as evidence but is consistently treated less favourably by courts and FTS auditors than documents generated at the time of performance.
Third, conduct an Article 54.1 readiness assessment of your distribution chain. If your Russian importer distributes through sub-distributors, consider whether those sub-distributors would withstand FTS scrutiny as genuine economic participants. Companies that cannot affirmatively answer that question are carrying exposure they may not have quantified.
Fourth, engage Russian tax counsel before the audit opens, not at the objection stage. Under Russian tax procedure, a significant proportion of the evidentiary and argumentative work available to a taxpayer occurs during the audit itself – through responses to inspector requests, the submission of documents, and the conduct of meetings with auditors. The objection and appeal stages are important, but they are far less effective if the audit record has not been constructed carefully.
Fifth, where arrangements have already been subject to audit and resulted in adverse findings, consider the full appeals pathway – including both the administrative route through the FTS and, where appropriate, the judicial route through the arbitrazh courts. Recent court practice suggests that the standard of review on appeal is not merely deferential to FTS findings: courts have, in well-documented cases, overturned assessments where the taxpayer presented structured economic evidence of genuine substance.
"The shift in 2026 is not merely procedural: courts are now applying a substantive economic reality test to pharmaceutical sector arrangements that previously passed documentary review without difficulty." — Kristina Kornouhova, Senior Lawyer, Practice Lead — Tax & Antitrust, Vetrov & Partners
Q: What specifically changed in how Russian courts apply Article 54.1 to pharmaceutical companies in 2026?
A: The principal change is the move from a documentary standard to a substantive economic reality standard. Courts previously focused on whether the taxpayer held the correct documents – contracts, invoices, acceptance certificates – to support a transaction. The approach now dominant in court practice requires the taxpayer to demonstrate that its counterparty possessed real economic capacity to perform: qualified personnel, physical infrastructure, and sector-specific resources. In the pharmaceuticals context, this is particularly significant for distribution intermediaries and intra-group service providers, where the gap between formal legal performance and actual economic substance is most visible to auditors.
Q: Which categories of foreign-owned pharmaceutical entities are most directly affected by this enforcement trend?
A: The highest-exposure categories are: foreign-owned Russian manufacturing or packaging entities receiving intra-group supply of ingredients or know-how; multi-tier distribution chains where intermediate entities lack verifiable logistics infrastructure; Russian subsidiaries contracting with foreign group members for regulatory affairs, pharmacovigilance, or clinical support services; and EAEU-oriented structures where pricing decisions reflect group-wide strategy rather than standalone Russian entity economics. Entities in any of these categories that have not updated their documentation since the FTS intensified its sectoral focus should treat this as a priority review item.
Q: What should an in-house counsel at a foreign pharmaceutical company do now to reduce Article 54.1 exposure in Russia?
A: The most effective steps are: conduct a substance audit of each Russian entity in the supply or service chain; compile or update contemporaneous records of actual service delivery and counterparty performance; review your distribution chain for entities that could not withstand FTS scrutiny as genuine economic participants; and engage experienced Russian tax controversy counsel before an audit opens. The evidentiary record that matters most in an Article 54.1 dispute is built during the audit, not during the objection or judicial appeal stage. Early engagement with counsel who understands both the procedural requirements and the sector-specific substance arguments is the most cost-effective risk-management step available.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry